9
Onco
l
Vol 7
l
Nr 3
l
2013
op de sterfte aan borstkanker zou een enorm aantal vrouwen
gedurende minstens 20 jaar moeten worden gevolgd. Het zou
best kunnen dat er nooit een dergelijke studie zal worden uit-
gevoerd. Bovendien verbeteren de beeldvormingstechnieken
te snel om op die manier te kunnen worden geëvalueerd. Wij
menen dan ook dat het geen zin heeft om te wachten op de
resultaten van een dergelijke studie om onze klinische praktijk
aan te passen en dat de tijd gekomen is voor screening op
maat (31).
Referenties
1.
American Cancer Society. Global cancer facts and figures 2008. (http://www.cancer.org/acs/
groups/content/ @epidemiologysurveilance/documents/ document/acspc-027766.pdf.)
2.
Lietzen LW, Sørensen GV, Ording AG. Survival of women with breast cancer in central and
northern Denmark, 1998-2009. Clin Epidemiol 2011;3(Suppl 1):35-40.
3.
Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighbouring European
countries with different levels of screening but similar access to treatment: trend analysis of
WHO mortality database. BMJ 2011;343:d4411.
4.
Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane
Database Syst Rev 2011 Jan 19;(1):CD001877.
5.
Autier P, Boniol M, Middleton R. Advanced breast cancer incidence following population-
based mammographic screening. Ann Oncol 2011;22:1726-35.
6.
Suhrke P, Mæhlen J, Schlichting E, et al. Effect of mammography screening on surgical
treatment for breast cancer in Norway: comparative analysis of cancer registry data. BMJ
2011;343:1-8.
7.
Burton RC, Bell RJ, Thiagarajah G, Stevenson C. Adjuvant therapy, not mammographic
screening, accounts for most of the observed breast cancer specific mortality reductions in
Australian women since the national screening program began in 1991. Breast Cancer Res
Treat 2012;131(3):949-55.
8.
Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG.
Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst
2006;98:774-82.
9.
Ahern CH, Shen Y. Cost-effectiveness analysis of mammography and clinical breast
examination strategies: a comparison with current guidelines. Cancer Epidemiol Biomarkers
Prev 2009;18:718-25.
10. Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammography by breast
density and other risk factors for breast cancer: Analysis of health enefits and cost-
effectiveness. Ann Intern Med 2011;155:10-20.
11. Lowery JT, Byers T, Hokanson JE, et al. Complementary approaches to assessing risk factors
for interval breast cancer. Cancer Causes Control 2011;22:23-31.
12. Olsen AH, Bihrmann K, Jensen MB, Vejborg I, Lynge E. Breast density and outcome of
mammography screening: a cohort study. Br J Cancer 2009;100(7):1205-8.
13. Checka CM, Chun JE, Schnabel FR, Lee J, Toth H. The relationship of mammographic density
and age: implications for breast cancer screening. Am J Roentgenol 2012;198(3):292-5.
14. Kerlikowske K, Cook A, Buist DSM, et al. Breast cancer risk by breast density, age,
menopause, and postmenopausal hormone therapy use. J Clin Oncol 2010;28(24):3830-7.
15. Yaghjyan L, Colditz GA, Collins LC, et al. Mammographic breast density and subsequent risk
of breast cancer in postmenopausal women according to tumor characteristics. J Natl
Cancer Inst 2011;103:1179-89.
16. Eerola H, Heikkila P, Tamminen A, et al. Histopathological features of breast tumours in
BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res
2005;7(1):R93-R100.
17. Nelson HD, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to
49 years: a systematic review and meta-analysis. Ann Intern Med 2012;156(9):635-48.
18. FH01 collaborative teams. Mammographic surveillance in women younger than 50 years
who have a family history of breast cancer: tumour characteristics and projected effect on
mortality in the prospective, single-arm, FH01 study. Lancet Oncol 2010;11:1127-34.
19. Lowry KP, Lee JM, Kong CY, et al. Annual screening strategies in BRCA1 and BRCA2 gene
mutation carriers: A comparative effectiveness analysis. Cancer 2012;118(8):2021-30.
20. Nederend J, Duijm LE, Louwman MW, Groenewoud JH, Donkers-van Rossum AB, Voogd
AC. Impact of transition from analog screening mammography to digital screening
mammography on screening outcome in The Netherlands: a population-based study. Ann
Oncol 2012;23(12):3098-103.
21. Corsetti V, Houssami N, Ghirardi M, et al. Evidence of the effect of adjunct ultrasound
screening in women with mammography-negative dense breasts: Interval breast cancers at 1
year follow-up. Eur J Cancer 2011;47(7):1021-6.
22. Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual
screening ultrasound or a single screening MRI to mammography in women with elevated
breast cancer risk. JAMA 2012;307(13):1394-404.
23. Nothacker M, Duda V, Hahn M, et al. Early detection of breast cancer: benefits and risks of
supplemental breast ultrasound in asymptomatic women with mammographically dense
breast tissue. A systematic review. BMC Cancer 2009;9:335.
24. Morrow M, Waters J, Morris E, et al. MRI for breast cancer screening, diagnosis, and
treatment. Lancet 2011;378(9805):1804-11.
25. Lifrange E, Bleret V, Desreux J, et al. [Benefits and limitations of mammography]. Rev Med
Liege 2003;58(5):331-7.
26. Warner E. Breast-cancer screening. N Engl J Med 2011;365:1025-32.
27. del Carmen MG, Halpern EF, Kopans DB, et al. Mammographic breast density and race. Am J
Roentgenol 2007;188:1147-50.
28. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival:
a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009;113:357-70.
29. Kopans DB. Basic physics and doubts about relationship between mammographically
determined tissue density and breast cancer risk. Radiology 2008;246(2):348-53.
30. Mathieu E, Barrat A, Davey HM, et al. Informed choice in mammography screening. Arch Int
Med 2007;167(19):2039-46.
31. Desreux J, Bleret V, Lifrange E. Should we individualize breast cancer screening? Maturitas
2012;73:202-5.
Ontvangen: 24/12/2012 Aanvaard: 04/01/2013
AVASTIN
®
in één oogopslag
AVASTIN
®
(bevacizumab) is een monoklonaal antilichaam
dat de binding van VEGF aan zijn receptoren die zich aan de
oppervlakte van de endotheelcellen bevinden, remt en aldus
de neoangiogenese verhindert.
AVASTIN
®
is één van de meest bestudeerde antitumorale
middelen ter wereld en is geautoriseerd in 123 landen voor
5 types kanker (colorectale, borst-, eierstok-, nier-,
en longkanker).
De minisite
roche-avastin.rmnet-corner.be geeft voor elke
indicatie een samenvatting van de terugbetalingsvoorwaarden
en de belangrijkste klinische gegevens.
De site is toegankelijk voor de lezers van de site ONCO-HEMATO
www.oncohemato.be
e